In Vitro Combination of Voriconazole and Miltefosine against Clinically Relevant Molds | Zendy

Sébastien Imbert | Zendy; M. Palous | Zendy; I. Meyer | Zendy; Éric Dannaoui | Zendy; Dominique Mazier | Zendy; A. Datry | Zendy; Arnaud Fekkar | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Combination of Voriconazole and Miltefosine against Clinically Relevant Molds

Author(s) -

Sébastien Imbert,

M. Palous,

I. Meyer,

Éric Dannaoui,

Dominique Mazier,

A. Datry,

Arnaud Fekkar

Publication year - 2014

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.03212-14

Subject(s) - voriconazole , miltefosine , antagonism , biology , azole , microbiology and biotechnology , drug resistance , antifungal , aspergillosis , pharmacology , combination therapy , medicine , immunology , leishmaniasis , receptor , visceral leishmaniasis

Invasive infections caused by filamentous fungi are a major threat for immunocompromised patients. Innate/acquired resistance to antifungal drugs might necessitate combination therapies. We assessed the potential combination of voriconazole with miltefosine, an original drug with antifungal activity against 33 clinically relevant mold isolates, including both azole-susceptible and -resistant Aspergillus. Using complete inhibition as an endpoint, interactions were indifferent for 32/33 isolates. An alternative 50% inhibition endpoint showed synergistic interactions for 14/33 isolates. Antagonism was absent.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research